Pembrolizumab KEYNOTE-001: an adaptive study leading to accelerated approval for two indications and a companion diagnosticThe landscape of cancer treatment has undergone a vast change over the past four decades [1, 2]. Discovery of the heterogeneous molecular features of tumors and the associated ...
[6]Robert C, Ribas A, Schachter J, et al. Pembrolizumab versus ipilimumab in advanced melanoma (KEYNOTE-006): post-hoc 5-year results from an open-label, multicentre, randomised, controlled, phase 3 study. Lancet Oncol. 2019 Sep;20(9):1239-1251....
2. Five-Year Overall Survival for Patients With Advanced Non‒Small-Cell Lung Cancer Treated With Pembrolizumab: Results From the Phase I KEYNOTE-001 Study. Published at jco.org on June 2, 2019. 3. Garon EB, Rizvi NA, Hui R, Leighl N, Balmanoukian AS, Eder JP, et al. Pembrolizumab...
Poor work-life balance is a major problem in the veterinary industry and among the top reasons these professionals may be inclined to leave the field, according to a recent Study.1 Led by Veterinary Integration Solutions and Galaxy Vets,... ...
Methods KEYNOTE-001 is a multicohort, open-label, phase 1 study of pembrolizumab (2 mg/kg every 3 weeks or 10 mg/kg every 2 or 3 weeks) in treatment naive or previously treated patients with locally advanced or metastatic non-small-cell lung cancer with measurable disease at baseline. ...
A Branch of International Law or an Undermining Factor to International Law: A Study on the Development of Space LawZhuoyan LuInternational Institute of Space Law